Name: Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing (Video) | JoVE Journal
Uploaded: 2023-01-20T13:20:00.000+00:00
Duration: 8 min 55 s
Description: Learn to formulate mRNA-lipid nanoparticles using microfluidic mixing for in vitro and in vivo delivery. This protocol enables consistent LNP production and potency evaluation in HepG2 cells and C57BL/6 mice.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

M.J.M. acknowledges support from a US National Institutes of Health (NIH) Director&#8217;s New Innovator Award (DP2 TR002776), a Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI), a US National Science Foundation CAREER award (CBET-2145491), and additional funding from the National Institutes of Health (NCI R01 CA241661, NCI R37 CA244911, and NIDDK R01 DK123049).

NOTE: Always maintain RNase-free conditions when formulating mRNA-LNPs by wiping the surfaces and equipment with a surface decontaminant for RNases and DNA. Use only RNase-free tips and reagents.
All the animal procedures were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals at the University of Pennsylvania and a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania.
1. Pre-formulation preparation
<ol>
	<li>Fill a clean 4 L beaker with 200-300 mL of fresh 10x phosphate-buffered saline (PBS).
	<ol>
		<li>Dilute the 10x PBS in the beaker 10-fold with ultrapure water to obtain a beaker of 1x PBS. Ensure that the final volume of the 1x PBS is between 2-3 L.</li>
		<li>Place dialysis cassettes (20 kDa molecular weight cutoff [MWCO]) of the appropriate capacity for the LNP formulation into the filled beaker to hydrate them. 
		NOTE: Dialysis cassettes require a minimum of 2 min to hydrate before use.</li>
		<li>Place a stir bar into the beaker, and cover the beaker with aluminum foil.</li>
		<li>Place the covered beaker onto a magnetic stir plate. Turn on the stir plate, and set it to spin at 300-400 rpm.</li>
	</ol>
	</li>
	<li>Dilute a 100 mM citric acid buffer stock (pH 3) 10-fold with ultrapure water to create the 10 mM citric acid buffer used for mRNA dilution.</li>
	<li>Make C12-200 ionizable lipid, helper lipid, cholesterol, and lipid-anchored PEG (lipid-PEG) stock solutions by dissolving each lipid in 100% ethanol. The concentrations of the lipid components are detailed in Table 1.
	<ol>
		<li>Heat and mix the stock solutions at 37 &#176;C to ensure that they are fully dissolved.</li>
	</ol>
	</li>
</ol>
2. Preparation of the lipid and nucleic acid mixes
<ol>
	<li>Calculate the required volumes of ionizable lipid, helper lipid, cholesterol, and lipid-PEG based on the desired molar ratio and ionizable lipid to mRNA weight ratio (Table 1). Prepare 10% extra volume of the organic phase to account for dead volume in the syringes during formulation.
	<ol>
		<li>Combine the calculated volumes of the different lipid components in a conical tube.</li>
		<li>Dilute the lipids with 100% ethanol to a final volume, V, which represents 25% of the final volume of LNP.</li>
	</ol>
	</li>
	<li>Calculate the amount of mRNA required for formulation based on the ionizable lipid to mRNA weight ratio and the total volume of mRNA-LNP needed (Table 1).
	<ol>
		<li>Thaw the firefly luciferase-encoding mRNA on ice.</li>
		<li>Dilute the mRNA to a final volume, 3V, three times the volume of the organic phase, in 10 mM citric acid buffer. 
		&#8203;NOTE: Every lipid volume, V, must contain enough ionizable lipid for the mRNA diluted in 3V. This corresponds to the desired ionizable lipid to mRNA weight ratio.</li>
	</ol>
	</li>
</ol>
3. Microfluidic formulation of mRNA-LNPs
<ol>
	<li>Spray a delicate task wipe with a surface decontaminant for RNases and DNA, and wipe the interior of the microfluidic instrument thoroughly.
	<ol>
		<li>Open a new microfluidic cartridge, and insert it with the inlet channels facing down and away.</li>
		<li>Ensure that the conical tube arm holds two 15 mL conical tubes and is in the position furthest to the right.</li>
		<li>Configure two sterile 15 mL conical tubes on the holder with the caps off.</li>
	</ol>
	</li>
	<li>Fill a 5 mL syringe with the mRNA solution that contains mRNA diluted in 10 mM citric acid buffer.
	<ol>
		<li>Fill a 3 mL syringe with the lipid solution that contains the lipids diluted in pure 100% ethanol.</li>
		<li>Flip up the cartridge holder on the microfluidic device.</li>
		<li>Insert the 5 mL syringe, without the needle, that contains mRNA into the left inlet of the cartridge.</li>
		<li>Insert the 3 mL syringe, without the needle, that contains lipids into the right inlet of the cartridge.</li>
		<li>Flip the cartridge holder back down, and close the lid of the microfluidic instrument.</li>
	</ol>
	</li>
	<li>Turn on the microfluidic instrument by using the switch located on the back of the instrument.
	<ol>
		<li>Select Quick Run.</li>
		<li>Select the correct syringe types for the 5 mL and 3 mL syringes inserted.</li>
		<li>Input the parameters for mRNA-LNP formulation at a 3:1 aqueous to organic flow rate ratio as described in Table 2.</li>
		<li>Press the Next button to go to the next screen.</li>
		<li>Confirm that the correct parameters have been inputted.</li>
		<li>Press the Start button to formulate the mRNA-LNPs.</li>
	</ol>
	</li>
</ol>
4. Post-formulation processing and characterization of the mRNA-LNPs
<ol>
	<li>Load the mRNA-LNPs collected in the right conical tube into the previously hydrated dialysis cassettes. 
	NOTE: Do not puncture or damage the membrane of the cassette when loading the mRNA-LNPs. If the membrane is damaged, mRNA-LNPs will be lost upon loading.
	<ol>
		<li>Place the dialysis cassettes containing the mRNA-LNPs back into the beaker containing 1x PBS, and leave them to dialyze for a minimum of 2 h.</li>
		<li>After dialysis, bring the dialysis cassettes containing the mRNA-LNPs into a sterile biosafety cabinet, and remove the mRNA-LNPs using a syringe with a needle.</li>
		<li>Sterile-filter the mRNA-LNPs using a 0.22 &#181;m syringe filter, and collect them in a sterile conical tube.</li>
		<li>Place 65 &#181;L of the mRNA-LNP solution into a 1.5 mL microtube for characterization purposes.</li>
	</ol>
	</li>
	<li>Dilute 10 &#181;L of mRNA-LNPs 1:100 in 990 &#181;L of 1x PBS in a cuvette for the measurement of the hydrodynamic size and polydispersity index using dynamic light scattering.</li>
	<li>Assess the concentration and encapsulation efficiency of the mRNA-LNPs using a fluorescence assay (i.e., RiboGreen).
	<ol>
		<li>Prepare a stock solution of 1x TE buffer by diluting 20x TE buffer with molecular biology water.</li>
		<li>Prepare a stock solution of 1% Triton X-100 buffer by diluting Triton X-100 with 1x TE buffer.</li>
		<li>Prepare the fluorescent reagent by diluting the reagent stock 1:200 with 1x TE buffer.</li>
		<li>Dilute the mRNA-LNPs 1:100 in 1x TE buffer and 1% Triton X-100 buffer in a black-wall black-bottom 96-well plate in 100 &#181;L.</li>
		<li>Prepare a low-range standard curve by diluting the RNA standard as per the manufacturer&#39;s instructions, and plate the standard curve in the 96-well plate.</li>
		<li>Add 100 &#181;L of diluted fluorescent reagent to each well containing diluted mRNA-LNP or diluted standard.</li>
		<li>Place the 96-well plate inside a plate reader, and shake for 1 min, followed by a 4 min wait.</li>
		<li>Measure the fluorescence intensity of each well according to the manufacturer&#39;s protocol at an excitation/emission of 480 nm/520 nm.</li>
	</ol>
	</li>
	<li>Use the standard curve to convert the fluorescence values to concentrations.
	<ol>
		<li>Calculate the encapsulation efficiency by subtracting the value obtained from diluting LNPs in TE buffer (unencapsulated mRNA) from the value obtained from diluting LNPs in 1% Triton X-100 (total mRNA) and dividing by the value obtained from diluting LNPs in 1% Triton X-100, according to equation 4.4.</li>
		<li>Calculate the mRNA-LNP concentration used for cell and animal studies by subtracting the value obtained from diluting LNPs in TE buffer (unencapsulated mRNA) from the value obtained from diluting LNPs in 1% Triton X-100 (total mRNA).</li>
	</ol>
	</li>
	<li>Measure the pKa of the mRNA-LNPs by performing a 6-(p-toluidino)-2-naphthalenesulfonyl chloride (TNS) assay.
	<ol>
		<li>Prepare the TNS reagent by creating a 0.16 mM solution of TNS in ultrapure water. 
		NOTE: When using the reagent, be sure to keep it on ice and away from light to avoid degradation.</li>
		<li>Prepare buffered solutions of 150 mM sodium chloride, 20 mM sodium phosphate, 25 mM ammonium citrate, and 20 mM ammonium acetate adjusted to different pH values ranging from 2 to 12 in increments of 0.5.</li>
		<li>Add 2.5 &#181;L of the LNP to each pH-adjusted buffer solution in a black-wall black-bottom 96-well plate.</li>
		<li>Add TNS reagent to each well so that the final TNS concentration is 6 &#181;M.</li>
		<li>Incubate the 96-well plate in a dark location for 5 min.</li>
		<li>Measure the fluorescence at an excitation/emission of 322 nm/431 nm using a fluorescence plate reader.</li>
		<li>Fit the data to a sigmoidal curve, and calculate the pKa by using the fitted equation to find the pH at which 50% of the maximum intensity was observed.</li>
	</ol>
	</li>
	<li>Representative results for the mRNA-LNP hydrodynamic size, PDI, encapsulation efficiency, and pKa are shown in Table 3.</li>
</ol>
5. In vitro transfection of HepG2 cells
NOTE: Various other cell lines, such as HeLa cells or HEK-293T cells, may be used for assessing the transfection efficiency of LNPs in vitro. All cells should test negative for mycoplasma prior to the LNP transfection studies.
<ol>
	<li>Plate 5,000 HepG2 cells in each well of a white-wall clear-bottom 96-well plate in 100 &#181;L of complete cell culture medium (DMEM supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin)
	<ol>
		<li>Leave the cells to adhere overnight in a controlled CO2 incubator at 37 &#176;C and 5% CO2.</li>
	</ol>
	</li>
	<li>Dilute the mRNA-LNPs in complete cell culture medium so that the total dose is delivered in 100 &#181;L.
	<ol>
		<li>Remove the complete medium from the wells.</li>
		<li>Treat the cells with either mRNA-LNPs diluted in complete cell culture medium at the desired doses or complete medium (control).</li>
		<li>Place the 96-well plate containing the treated cells back into the controlled CO2 incubator for 24 hours.</li>
	</ol>
	</li>
	<li>Assess the transfection efficiency by performing a luciferase assay.
	<ol>
		<li>Prepare the luciferase reagent and 1x cell lysis buffer as per the manufacturer&#39;s instructions.</li>
		<li>Take out the 96-well plate containing the cells from the incubator, and bring it into a biosafety cabinet.</li>
		<li>Remove the cell culture medium from every well of the 96-well plate.</li>
		<li>Add 20 &#181;L of 1x lysis buffer to each well, followed by 100 &#181;L of the previously prepared luciferase assay reagent.</li>
		<li>Protect the plate from light, and place the plate into a plate reader to measure the bioluminescent signal of each well. 
		&#8203;NOTE: Representative results demonstrating the treatment of HepG2 cells with previously formulated C12-200 mRNA-LNPs are shown in Figure 1.</li>
	</ol>
	</li>
</ol>
6. In vivo evaluation of mRNA-LNPs in mice following tail vein injection
<ol>
	<li>Dilute the mRNA-LNP solution with sterile 1x PBS so that 2 &#181;g of total mRNA is present in a 100 &#181;L tail vein injection volume, which corresponds to a body weight dose of approximately 0.1 mg/kg for a 20 g mouse.</li>
	<li>Restrain each mouse using an approved method, and wipe the tail with a pad moistened with 70% alcohol.
	<ol>
		<li>Fill a 29 G insulin syringe with either 100 &#181;L of mRNA-LNP (2 &#181;g) or 100 &#181;L of 1x PBS. Remove any bubbles from the syringe.</li>
		<li>Insert the needle with the bevel facing up into the mouse&#39;s lateral tail vein, and slowly inject the 100 &#181;L of mRNA-LNP or 1x PBS.</li>
		<li>Remove the needle and apply pressure until hemostasis is achieved.</li>
	</ol>
	</li>
	<li>Prepare a stock solution of 15 mg/mL d-luciferin potassium salt in sterile 1x PBS 6 hours post injection.
	<ol>
		<li>Turn on the in vivo imaging system (IVIS), and open the imaging software.</li>
		<li>Press Initialize to prepare the instrument for data acquisition.</li>
		<li>Check the box next to luminescence, and set the exposure time to auto. Ensure that the correct field of view is selected for the number of mice being imaged.</li>
		<li>Administer 200 &#181;L of d-luciferin intraperitoneally (150 mg of luciferin per kg body weight) to the previously treated mice.</li>
		<li>Place the mice into an anesthesia chamber set to 2.5% isoflurane and an oxygen flowrate of 2.0 L/min.</li>
		<li>Wait 10 min for the luciferase signal to stabilize before imaging the mRNA-LNP-treated mice.</li>
		<li>Ensure that the mice are fully anesthetized, and redirect the anesthetic line to administer isoflurane via nose cones inside the imaging chamber.</li>
		<li>Transfer the mice to the nose cones, and ensure that they are on their backs with their abdomens exposed.</li>
		<li>Close the chamber door, and click the Acquire button in the software to obtain bioluminescence images. 
		NOTE: Representative results for mouse whole-body imaging following mRNA-LNP or 1X PBS treatment are shown in Figure 2.</li>
	</ol>
	</li>
</ol>

<ol><li>Cheng, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Selective+organ+targeting+%28SORT%29+nanoparticles+for+tissue-specific+mRNA+delivery+and+CRISPR-Cas+gene+editing%5BTitle%5D)+AND+%22Nature+Nanotechnology%22%5BJournal%5D)">Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing.</a> Nature Nanotechnology. 15 (4), 313-320 (2020).</li>
<li>Wood, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((FDA+approves+patisiran+to+treat+hereditary+transthyretin+amyloidosis%5BTitle%5D)+AND+%22Nature+Reviews+Neurology%22%5BJournal%5D)">FDA approves patisiran to treat hereditary transthyretin amyloidosis.</a> Nature Reviews Neurology. 14 (9), 509(2018).</li>
<li>Zhang, X., Goel, V., Robbie, G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Pharmacokinetics+of+patisiran%2C+the+first+approved+RNA+interference+therapy+in+patients+With+hereditary+transthyretin-mediated+amyloidosis%5BTitle%5D)+AND+%22Journal+of+Clinical+Pharmacology%22%5BJournal%5D)">Pharmacokinetics of patisiran, the first approved RNA interference therapy in patients With hereditary transthyretin-mediated amyloidosis.</a> Journal of Clinical Pharmacology. 60 (5), 573-585 (2019).</li>
<li>Shepherd, S. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Scalable+mRNA+and+siRNA+lipid+nanoparticle+production+using+a+parallelized+microfluidic+device%5BTitle%5D)+AND+%22Nano+Letters%22%5BJournal%5D)">Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device.</a> Nano Letters. 21 (13), 5671-5680 (2021).</li>
<li>Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., Anderson, D. G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+clinical+progress+of+mRNA+vaccines+and+immunotherapies%5BTitle%5D)+AND+%22Nature+Biotechnology%22%5BJournal%5D)">The clinical progress of mRNA vaccines and immunotherapies.</a> Nature Biotechnology. 40 (6), 840-854 (2022).</li>
<li>Mukalel, A. J., Riley, R. S., Zhang, R., Mitchell, M. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nanoparticles+for+nucleic+acid+delivery%3A+Applications+in+cancer+immunotherapy%5BTitle%5D)+AND+%22Cancer+Letters%22%5BJournal%5D)">Nanoparticles for nucleic acid delivery: Applications in cancer immunotherapy.</a> Cancer Letters. 458, 102-112 (2019).</li>
<li>Akhtar, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Oral+delivery+of+siRNA+and+antisense+oligonucleotides%5BTitle%5D)+AND+%22Journal+of+Drug+Targeting%22%5BJournal%5D)">Oral delivery of siRNA and antisense oligonucleotides.</a> Journal of Drug Targeting. 17 (7), 491-495 (2009).</li>
<li>Guimaraes, P. P. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Ionizable+lipid+nanoparticles+encapsulating+barcoded+mRNA+for+accelerated+in+vivo+delivery+screening%5BTitle%5D)+AND+%22Journal+of+Controlled+Release%22%5BJournal%5D)">Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening.</a> Journal of Controlled Release. 316, 404-417 (2019).</li>
<li>Qiu, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lipid+nanoparticle-mediated+codelivery+of+Cas9+mRNA+and+single-guide+RNA+achieves+liver-specific+in+vivo+genome+editing+of+Angptl3%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3.</a> Proceedings of the National Academy of Sciences of the United States of America. 118 (10), 2020401118(2021).</li>
<li>Zhang, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Helper+lipid+structure+influences+protein+adsorption+and+delivery+of+lipid+nanoparticles+to+spleen+and+liver%5BTitle%5D)+AND+%22Biomaterials+Science%22%5BJournal%5D)">Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver.</a> Biomaterials Science. 9 (4), 1449-1463 (2021).</li>
<li>El-Mayta, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+nanoparticle+platform+for+accelerated+in+vivo+oral+delivery+screening+of+nucleic+acids%5BTitle%5D)+AND+%22Advanced+Therapeutics%22%5BJournal%5D)">A nanoparticle platform for accelerated in vivo oral delivery screening of nucleic acids.</a> Advanced Therapeutics. 4 (1), 2000111(2021).</li>
<li>Patel, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Naturally-occurring+cholesterol+analogues+in+lipid+nanoparticles+induce+polymorphic+shape+and+enhance+intracellular+delivery+of+mRNA%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA.</a> Nature Communications. 11, 983(2020).</li>
<li>Kulkarni, J. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Design+of+lipid+nanoparticles+for+in+vitro+and+in+vivo+delivery+of+plasmid+DNA%5BTitle%5D)+AND+%22Nanomedicine%3A+Nanotechnology%2C+Biology%2C+and+Medicine%22%5BJournal%5D)">Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA.</a> Nanomedicine: Nanotechnology, Biology, and Medicine. 13 (4), 1377-1387 (2017).</li>
<li>Cheng, X., Lee, R. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+role+of+helper+lipids+in+lipid+nanoparticles+%28LNPs%29+designed+for+oligonucleotide+delivery%5BTitle%5D)+AND+%22Advanced+Drug+Delivery+Reviews%22%5BJournal%5D)">The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.</a> Advanced Drug Delivery Reviews. 99, 129-137 (2016).</li>
<li>Varkouhi, A. K., Scholte, M., Storm, G., Haisma, H. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Endosomal+escape+pathways+for+delivery+of+biologicals%5BTitle%5D)+AND+%22Journal+of+Controlled+Release%22%5BJournal%5D)">Endosomal escape pathways for delivery of biologicals.</a> Journal of Controlled Release. 151 (3), 220-228 (2011).</li>
<li>Granot, Y., Peer, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Delivering+the+right+message%3A+Challenges+and+opportunities+in+lipid+nanoparticles-mediated+modified+mRNA+therapeutics-An+innate+immune+system+standpoint%5BTitle%5D)+AND+%22Seminars+in+Immunology%22%5BJournal%5D)">Delivering the right message: Challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint.</a> Seminars in Immunology. 34, 68-77 (2017).</li>
<li>Gan, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Nanoparticles+containing+constrained+phospholipids+deliver+mRNA+to+liver+immune+cells+in+vivo+without+targeting+ligands%5BTitle%5D)+AND+%22Bioengineering+and+Translational+Medicine%22%5BJournal%5D)">Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands.</a> Bioengineering and Translational Medicine. 5 (3), 10161(2020).</li>
<li>Patel, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hydroxycholesterol+substitution+in+ionizable+lipid+nanoparticles+for+mRNA+delivery+to+T+cells%5BTitle%5D)+AND+%22Journal+of+Controlled+Release%22%5BJournal%5D)">Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells.</a> Journal of Controlled Release. 347, 521-532 (2022).</li>
<li>Robinson, E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lipid+nanoparticle-delivered+chemically+modified+mRNA+restores+chloride+secretion+in+cystic+fibrosis%5BTitle%5D)+AND+%22Molecular+Therapy%22%5BJournal%5D)">Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis.</a> Molecular Therapy. 26 (8), 2034-2046 (2018).</li>
<li>Love, K. T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lipid-like+materials+for+low-dose%2C+in+vivo+gene+silencing%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Lipid-like materials for low-dose, in vivo gene silencing.</a> Proceedings of the National Academy of Sciences of the United States of America. 107 (5), 1864-1869 (2010).</li>
<li>Kauffman, K. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+lipid+nanoparticle+formulations+for+mRNA+delivery+in+vivo+with+fractional+factorial+and+definitive+screening+designs%5BTitle%5D)+AND+%22Nano+Letters%22%5BJournal%5D)">Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs.</a> Nano Letters. 15 (11), 7300-7306 (2015).</li>
<li>Billingsley, M. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Ionizable+lipid+nanoparticle-mediated+mRNA+delivery+for+human+CAR+T+cell+engineering%5BTitle%5D)+AND+%22Nano+Letters%22%5BJournal%5D)">Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering.</a> Nano Letters. 20 (3), 1578-1589 (2020).</li>
<li>Ramaswamy, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Systemic+delivery+of+factor+IX+messenger+RNA+for+protein+replacement+therapy%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Systemic delivery of factor IX messenger RNA for protein replacement therapy.</a> Proceedings of the National Academy of Sciences of the United States of America. 114 (10), 1941-1950 (2017).</li>
<li>Leung, A. K. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lipid+nanoparticles+containing+siRNA+synthesized+by+microfluidic+mixing+exhibit+an+electron-dense+nanostructured+core%5BTitle%5D)+AND+%22Journal+of+Physical+Chemistry+C%22%5BJournal%5D)">Lipid nanoparticles containing siRNA synthesized by microfluidic mixing exhibit an electron-dense nanostructured core.</a> Journal of Physical Chemistry C. 116 (34), 18440-18450 (2012).</li>
<li>Billingsley, M. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Orthogonal+design+of+experiments+for+optimization+of+lipid+nanoparticles+for+mRNA+engineering+of+CAR+T+cells%5BTitle%5D)+AND+%22Nano+Letters%22%5BJournal%5D)">Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells.</a> Nano Letters. 22 (1), 533-542 (2022).</li>
<li>Khalil, A. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Subcutaneous+administration+of+D-luciferin+is+an+effective+alternative+to+intraperitoneal+injection+in+bioluminescence+imaging+of+xenograft+tumors+in+nude+mice%5BTitle%5D)+AND+%22ISRN+Molecular+Imaging%22%5BJournal%5D)">Subcutaneous administration of D-luciferin is an effective alternative to intraperitoneal injection in bioluminescence imaging of xenograft tumors in nude mice.</a> ISRN Molecular Imaging. 2013, 689279(2013).</li>
<li>Qin, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((RGD+peptide-based+lipids+for+targeted+mRNA+delivery+and+gene+editing+applications%5BTitle%5D)+AND+%22RSC+Advances%22%5BJournal%5D)">RGD peptide-based lipids for targeted mRNA delivery and gene editing applications.</a> RSC Advances. 12 (39), 25397-25404 (2022).</li>
<li>Pardi, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Expression+kinetics+of+nucleoside-modified+mRNA+delivered+in+lipid+nanoparticles+to+mice+by+various+routes%5BTitle%5D)+AND+%22Journal+of+Controlled+Release%22%5BJournal%5D)">Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.</a> Journal of Controlled Release. 217, 345-351 (2015).</li>
<li>Finn, J. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+single+administration+of+CRISPR%2FCas9+lipid+nanoparticles+achieves+robust+and+persistent+in+vivo+genome+editing%5BTitle%5D)+AND+%22Cell+Reports%22%5BJournal%5D)">A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing.</a> Cell Reports. 22 (9), 2227-2235 (2018).</li>
<li>Truong, B., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Lipid+nanoparticle-targeted+mRNA+therapy+as+a+treatment+for+the+inherited+metabolic+liver+disorder+arginase+deficiency%5BTitle%5D)+AND+%22Proceedings+of+the+National+Academy+of+Sciences+of+the+United+States+of+America%22%5BJournal%5D)">Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.</a> Proceedings of the National Academy of Sciences of the United States of America. 116 (42), 21150-21159 (2019).</li>
<li>Cheng, Q., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Dendrimer-based+lipid+nanoparticles+deliver+therapeutic+FAH+mRNA+to+normalize+liver+function+and+extend+survival+in+a+mouse+model+of+hepatorenal+tyrosinemia+type+I%5BTitle%5D)+AND+%22Advanced+Materials%22%5BJournal%5D)">Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I.</a> Advanced Materials. 30 (52), 1805308(2018).</li>
<li>Sedic, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Safety+evaluation+of+lipid+nanoparticle-formulated+modified+mRNA+in+the+Sprague-Dawley+rat+and+cynomolgus+monkey%5BTitle%5D)+AND+%22Veterinary+Pathology%22%5BJournal%5D)">Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey.</a> Veterinary Pathology. 55 (2), 341-354 (2018).</li>
<li>Veiga, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell+specific+delivery+of+modified+mRNA+expressing+therapeutic+proteins+to+leukocytes%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes.</a> Nature Communications. 9 (1), 4493(2018).</li>
<li>Pattipeiluhu, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anionic+lipid+nanoparticles+preferentially+deliver+mRNA+to+the+hepatic+reticuloendothelial+system%5BTitle%5D)+AND+%22Advanced+Materials%22%5BJournal%5D)">Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system.</a> Advanced Materials. 34 (16), 2201095(2022).</li>
<li>Rosenblum, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((CRISPR-Cas9+genome+editing+using+targeted+lipid+nanoparticles+for+cancer+therapy%5BTitle%5D)+AND+%22Science+Advances%22%5BJournal%5D)">CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.</a> Science Advances. 6 (47), (2020).</li>
<li>Fenton, O. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Bioinspired+alkenyl+amino+alcohol+ionizable+lipid+materials+for+highly+potent+in+vivo+mRNA+delivery%5BTitle%5D)+AND+%22Advanced+Materials%22%5BJournal%5D)">Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery.</a> Advanced Materials. 28 (15), 2939-2943 (2016).</li>
<li>Kauffman, K. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimization+of+lipid+nanoparticle+formulations+for+mRNA+delivery+in+vivo+with+fractional+factorial+and+definitive+screening+designs%5BTitle%5D)+AND+%22Nano+Letters%22%5BJournal%5D)">Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs.</a> Nano Letters. 15 (11), 7300-7306 (2015).</li>
<li>Tombácz, I., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Highly+efficient+CD4%2B+T+cell+targeting+and+genetic+recombination+using+engineered+CD4%2B+cell-homing+mRNA-LNPs%5BTitle%5D)+AND+%22Molecular+Therapy%22%5BJournal%5D)">Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs.</a> Molecular Therapy. 29 (11), 3293-3304 (2021).</li>
<li>Kim, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Engineering+lipid+nanoparticles+for+enhanced+intracellular+delivery+of+mRNA+through+inhalation%5BTitle%5D)+AND+%22Nano%22%5BJournal%5D)">Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation.</a> Nano. 9 (9), 14792-14806 (2022).</li>
<li>Bevers, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((mRNA-LNP+vaccines+tuned+for+systemic+immunization+induce+strong+antitumor+immunity+by+engaging+splenic+immune+cells%5BTitle%5D)+AND+%22Molecular+Therapy%22%5BJournal%5D)">mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells.</a> Molecular Therapy. 30 (9), 3078-3094 (2022).</li>
</ol>

There are no conflicts of interest to declare.

With this workflow, a variety of mRNA-LNPs can be formulated and tested for their in vitro and in vivo efficiency. Ionizable lipids and excipients can be swapped out and combined at different molar ratios and different ionizable lipid to mRNA weight ratios to produce mRNA-LNPs with differing physicochemical properties22. Here, we formulated C12-200 mRNA-LNPs with a molar ratio of 35/16/46.5/2.5 (ionizable lipid:helper lipid:cholesterol:lipid-PEG) at a 10:1 ionizable lipid to mRNA...

Lipid nanoparticles (LNPs) have demonstrated great promise in recent years in the field of non-viral gene therapy. In 2018, the United States Food and Drug Administration (FDA) approved the first-ever RNA interference (RNAi) therapeutic, Onpattro by Alnylam, for the treatment of hereditary transthyretin amyloidosis1,2,3,4. This was an important step forward for lipid nanoparticles and RNA-based therapies. More recently, Moderna and Pfizer/BioNTech received FDA approvals for their mRNA-LNP vaccines against SARS-CoV-24,5. In each of these LNP-based nucleic acid therapies, the LNP serves to protect its cargo from degradation by nucleases and facilitate potent intracellular delivery6,7. While LNPs have seen success in RNAi therapies and vaccine applications, mRNA-LNPs have also been explored for use in protein replacement therapies8 as well as for the co-delivery of Cas9 mRNA and guide RNA for the delivery of the CRISPR-Cas9 system for gene editing9. However, there is no one specific formulation that is well-suited for all applications, and subtle changes in the LNP formulation parameters can greatly affect the potency and biodistribution in vivo8,10,11. Thus, individual mRNA-LNPs must be developed and evaluated to determine the optimal formulation for each LNP-based therapy.
LNPs are commonly formulated with four lipid components: an ionizable lipid, a phospholipid, cholesterol, and a lipid-anchored polyethylene-glycol (PEG) conjugate (lipid-PEG)11,12,13. The potent intracellular delivery facilitated by LNPs relies, in part, on the ionizable lipid component12. This component is neutral at physiological pH but becomes positively charged in the acidic environment of the endosome11. This change in ionic charge is thought to be a key contributor to endosomal escape12,14,15. In addition to the ionizable lipid, the phospholipid (helper lipid) component improves the encapsulation of the cargo and aids in endosomal escape, the cholesterol offers stability and enhances membrane fusion, and the lipid-PEG minimizes LNP aggregation and opsonization in circulation10,11,14,16. To formulate the LNP, these lipid components are combined in an organic phase, typically ethanol, and mixed with an aqueous phase containing the nucleic acid cargo. The LNP formulation process is very versatile in that it allows for different components to be easily substituted and combined at different molar ratios in order to formulate many LNP formulations&#160;with a multitude of physicochemical properties10,17. However, when exploring this vast variety of LNPs, it is crucial that each formulation is evaluated using a standardized procedure to accurately measure the differences in characterization and performance.
Here, the complete workflow for the formulation of mRNA-LNPs and the assessment of their performance in cells and animals is outlined.

<table><tbody><tr><td>0.1 M Hydrochloric Acid</td><td>Sigma</td><td>7647-01-0</td><td></td></tr><tr><td>0.22 &amp;mu;m Syringe Filters</td><td>Genesee</td><td>25-243</td><td></td></tr><tr><td>1 mL BD Slip Tip Syringe</td><td>BD</td><td>309659</td><td></td></tr><tr><td>1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt) (C14-PEG2000)</td><td>Avanti Polar Lipids</td><td>880150P</td><td></td></tr><tr><td>1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)</td><td>Avanti Polar Lipids</td><td>850725P</td><td></td></tr><tr><td>1.5 mL Eppendorf Tubes</td><td>Fisher Scientific</td><td>05-408-129</td><td></td></tr><tr><td>15 mL Conical Tubes</td><td>Fisher Scientific</td><td>14-959-70C</td><td></td></tr><tr><td>200 proof Ethanol</td><td>Decon Labs</td><td>2716</td><td></td></tr><tr><td>23G Needles</td><td>Fisher Scientific</td><td>14-826-6C</td><td></td></tr><tr><td>3 mL BD Disposable Syringes with Luer-Lok tips</td><td>Fisher Scientific</td><td>14-823-435</td><td></td></tr><tr><td>3 mL Dialysis Cassettes</td><td>Thermo Scientific</td><td>A52976</td><td></td></tr><tr><td>96 Well Black Wall Black Bottom Plate</td><td>Fisher Scientific</td><td>07-000-135</td><td></td></tr><tr><td>96 Well White/Clear Bottom Plate, TC Surface</td><td>Thermo Scientific</td><td>165306</td><td></td></tr><tr><td>Ammonium Acetate, 1 Kilogram</td><td>Research Products International</td><td>&amp;nbsp;631-61-8</td><td></td></tr><tr><td>Ammonium Citrate dibasic</td><td>SIgma</td><td>3012-65-5</td><td></td></tr><tr><td>BD Luer-Lok Syringe sterile, single use, 5 mL</td><td>BD</td><td>309646</td><td></td></tr><tr><td>C12-200 Ionizable Lipid</td><td>Cayman Chemical</td><td>36699</td><td></td></tr><tr><td>C57BL/6 Mice</td><td>Jackson Laboratory</td><td>000664</td><td></td></tr><tr><td>Cholesterol</td><td>Sigma</td><td>57-88-5</td><td></td></tr><tr><td>CleanCap FLuc mRNA (5moU)</td><td>TriLink Biotechnologies</td><td>L-7202</td><td></td></tr><tr><td>Disposable cuvettes</td><td>Fisher Scientific</td><td>14955129</td><td></td></tr><tr><td>D-Luciferin, Potassium Salt</td><td>Thermo Scientific</td><td>L2916</td><td></td></tr><tr><td>DMEM, high glucose</td><td>Thermofisher Scientific</td><td>11965-084</td><td></td></tr><tr><td>Exel Insulin Syringes - 0.5 mL</td><td>Fisher Scientific</td><td>1484132</td><td></td></tr><tr><td>Fetal Bovine Serum</td><td>Corning</td><td>35-010-CV</td><td></td></tr><tr><td>Hep G2 [HEPG2]</td><td>ATCC</td><td>HB-8065</td><td></td></tr><tr><td>HyPure Molecular Biology Grade Water</td><td>Cytiva</td><td>SH30538.03</td><td></td></tr><tr><td>Infinite 200 PRO Plate Reader</td><td>Tecan</td><td>N/A</td><td></td></tr><tr><td>IVIS Spectrum In Vivo Imaging System</td><td>Perkin Elmer</td><td>N/A</td><td></td></tr><tr><td>Large Kimwipes</td><td>Fisher Scientific</td><td>06-666-11D</td><td></td></tr><tr><td>Luciferase Assay Kit</td><td>Promega</td><td>E4550</td><td></td></tr><tr><td>NanoAssemblr Ignite Cartridges - Classic - 100 Pack</td><td>Precision Nanosystems</td><td>NIN0065</td><td></td></tr><tr><td>NanoAssemblr Ignite Instrument</td><td>Precision Nanosystems</td><td>NIN0001</td><td></td></tr><tr><td>PBS - Phosphate-Buffered Saline (10x) pH 7.4, RNase-free</td><td>Thermo Scientific</td><td>AM9624</td><td></td></tr><tr><td>Penicillin-Streptomycin</td><td>Thermofisher Scientific</td><td>15140122</td><td></td></tr><tr><td>QB Citrate Buffer, (Citrate 100 mM) pH 3.0</td><td>Teknova</td><td>Q2442</td><td></td></tr><tr><td>Quant-it RiboGreen RNA Assay Kit</td><td>Thermo Scientific</td><td>R11490</td><td></td></tr><tr><td>Reporter Lysis 5x Buffer</td><td>Promega</td><td>E3971</td><td></td></tr><tr><td>RNase Away Surface Decontaminant</td><td>Thermofisher Scientific</td><td>7000TS1</td><td></td></tr><tr><td>Sodium Chloride</td><td>Sigma</td><td>7647-14-5</td><td></td></tr><tr><td>Sodium Hydroxide</td><td>Sigma</td><td>1310-73-2</td><td></td></tr><tr><td>Sodium Phosphate</td><td>Sigma</td><td>7601-54-9</td><td></td></tr><tr><td>TNS reagent (6-(p-Toluidino)-2-naphthalenesulfonic acid sodium salt)</td><td>Sigma</td><td>T9792</td><td></td></tr><tr><td>Triton X-100</td><td>Sigma</td><td>9036-19-5</td><td></td></tr><tr><td>Zetasizer</td><td>Malvern Panalytical</td><td>NanoZS</td><td></td></tr></tbody></table>

testing the in vitro and in vivo efficiency of mrna-lipid nanoparticles formulated by microfluidic mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Lipid nanoparticles (LNPs) have attracted widespread attention recently with the successful development of the COVID-19 mRNA vaccines by Moderna and Pfizer/BioNTech. These vaccines have demonstrated the efficacy of mRNA-LNP therapeutics and opened the door for future clinical applications. In mRNA-LNP systems, the LNPs serve as delivery platforms that protect the mRNA cargo from degradation by nucleases and mediate their intracellular delivery. The LNPs are typically composed of four components: an ionizable lipid, a phospholipid, cholesterol, and a lipid-anchored polyethylene glycol (PEG) conjugate (lipid-PEG). Here, LNPs encapsulating mRNA encoding firefly luciferase are formulated by microfluidic mixing of the organic phase containing LNP lipid components and the aqueous phase containing mRNA. These mRNA-LNPs are then tested in vitro to evaluate their transfection efficiency in HepG2 cells using a bioluminescent plate-based assay. Additionally, mRNA-LNPs are evaluated in vivo in C57BL/6 mice following an intravenous injection via the lateral tail vein. Whole-body bioluminescence imaging is performed by using an in vivo imaging system. Representative results are shown for the mRNA-LNP characteristics, their transfection efficiency in HepG2 cells, and the total luminescent flux in C57BL/6 mice.

mRNA-LNPs were formulated using a microfluidic instrument that possessed an average hydrodynamic diameter of 76.16 nm and a polydispersity index of 0.098. The pKa of the mRNA-LNPs was found to be 5.75 by performing a TNS assay18. The encapsulation efficiency for these mRNA-LNPs was calculated to be 92.3% by using the modified fluorescence assay and equation 4.4. The overall RNA concentration that was used for the cell treatment and animal dosing was 40.24 ng/µL...

Here, a protocol for formulating lipid nanoparticles (LNPs) that encapsulate mRNA encoding firefly luciferase is presented. These LNPs were tested for their potency in vitro in HepG2 cells and in vivo in C57BL/6 mice.

Lipid nanoparticles (LNPs) have attracted widespread attention recently with the successful development of the COVID-19 mRNA vaccines by Moderna and ...

testing-vitro-vivo-efficiency-mrna-lipid-nanoparticles-formulated

Research

JoVE Journal

Bioengineering

Here we describe a protocol for the generation of cationic nanoliposomes, which is based on the dry-film method and can be used for the safe and efficient delivery of in vitro transcribed messenger RNA.

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Here, a quantitative real-time polymerase chain reaction-based protocol is presented for the determination of the native micro-RNA content (absolute/relative) of lipoprotein particles. In addition, a method for increasing the micro-RNA level, as well as a method for determining the cellular uptake rate of lipoprotein particles, is demonstrated.

Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate

The protocol presents the optimized parameters for preparing thermosensitive liposomes using the staggered herringbone micromixer microfluidics device. This also allows co-encapsulation of doxorubicin and indocyanine green into the liposomes and the photothermal-triggered release of doxorubicin for controlled/triggered drug release.

Microfluidic Production of Lysolipid-Containing Temperature-Sensitive Liposomes

Lipid nanoparticles are developed using a microfluidic mixing platform approach for mRNA and DNA encapsulation.

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

A self-assembled peptide-poloxamine nanoparticle (PP-sNp) is developed using a microfluidic mixing device to encapsulate and deliver in vitro transcribed messenger RNA. The described mRNA/PP-sNp could efficiently transfect cultured cells in vitro.

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles

The present protocol prepares and evaluates the physical properties, immune response, and in vivo protective effect of a novel nanoemulsion adjuvant vaccine.

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

This protocol provides an approach to formulation optimization over mixture, continuous, and categorical study factors that minimizes subjective choices in the experimental design construction. For the analysis phase, an effective and easy-to-use modeling fitting procedure is employed.

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Here, we describe a magnetic separation-assisted high-speed homogenization method for large-scale production of endosome-derived nanovesicles as a new type of exosome mimics (EMs) that share the same biological origin and similar structure, morphology, and protein composition of native extracellular vesicles (EVs).

A Magnetic Separation-Assisted High-Speed Homogenization Method for Large-Scale Production of Endosome-Derived Vesicles

A detailed protocol for synthesizing lipid nanoparticles (LNPs) using confined impinging jet (CIJ) mixer technologies, including a two-jet CIJ and a four-jet multi-inlet vortex mixer (µMIVM), is demonstrated. The CIJ mixers generate reproducible, turbulent micro-mixing environments, resulting in the production of monodisperse LNPs.

Synthesizing Lipid Nanoparticles by Turbulent Flow in Confined Impinging Jet Mixers

This protocol presents Rayleigh breakup as a mild process for aerosolizing non-viral mRNA vectors. Regional deposition for aerosolized mRNA vectors is evaluated by the Alberta Idealized Nasal Inlet (AINI) model. Green fluorescence protein (GFP) expression in human lung cells represents maintenance of physicochemical and biological functions of post-aerosolized mRNA vectors.

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing

Learn to formulate mRNA-lipid nanoparticles using microfluidic mixing for in vitro and in vivo delivery. This protocol enables consistent LNP production and potency evaluation in HepG2 cells and C57BL/6 mice.

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Explore More Videos